These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19640511)

  • 1. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
    Meyer JM; McEvoy JP; Davis VG; Goff DC; Nasrallah HA; Davis SM; Hsiao JK; Swartz MS; Stroup TS; Lieberman JA
    Biol Psychiatry; 2009 Dec; 66(11):1013-22. PubMed ID: 19640511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
    Meyer JM; Davis VG; McEvoy JP; Goff DC; Nasrallah HA; Davis SM; Daumit GL; Hsiao J; Swartz MS; Stroup TS; Lieberman JA
    Schizophr Res; 2008 Aug; 103(1-3):104-9. PubMed ID: 18534821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
    Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
    Ramsey TL; Brennan MD
    Schizophr Res; 2014 Dec; 160(1-3):73-9. PubMed ID: 25449714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
    Volavka J; Czobor P; Citrome L; Van Dorn RA
    CNS Spectr; 2014 Oct; 19(5):374-81. PubMed ID: 24284234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
    McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
    Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What CATIE found: results from the schizophrenia trial.
    Swartz MS; Stroup TS; McEvoy JP; Davis SM; Rosenheck RA; Keefe RS; Hsiao JK; Lieberman JA
    Psychiatr Serv; 2008 May; 59(5):500-6. PubMed ID: 18451005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
    Meyer JM; Davis VG; Goff DC; McEvoy JP; Nasrallah HA; Davis SM; Rosenheck RA; Daumit GL; Hsiao J; Swartz MS; Stroup TS; Lieberman JA
    Schizophr Res; 2008 Apr; 101(1-3):273-86. PubMed ID: 18258416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schmid F; Hunger H; Schwarz S; Srisurapanont M; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006625. PubMed ID: 20091600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
    Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; Reimherr F; Miller DD; McGee M; Khan A; Canive JM; Davis SM; Hsiao JK; Lieberman JA;
    Schizophr Res; 2008 Mar; 100(1-3):39-52. PubMed ID: 18191383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
    BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.